RemedyRepack Carvedilol 25 mg Tablet, QTY: 30 Tablets per Blister Pack recall — FDA D-0217-2025
CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.
Overview of recall records associated with RemedyRepack Inc., including dates, categories and classifications where available.
Classification mix: Class II: 2.
CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.
CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.
This page summarizes recall records in which the official source identifies RemedyRepack Inc. as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.